Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
Clinical Study of CD19 Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Refractory Juvenile Dermatomyositis (RJDM)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Meiping Lu, M.D
- Phone Number: 13685773988
- Email: meipinglu@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- Children's Hospital ZheJiang University School of Medicine
-
Contact:
- Meiping Lu, M.D
- Phone Number: 13685773988
- Email: meipinglu@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: ≥5 years and <17 years old
- To meet the diagnostic criteria of JDM, four or five of the following criteria must be met:① symmetrical proximal muscle weakness; ②Characteristic skin changes, including positive dermatitis (purplish red rash on upper eyelid with periorbital edema) and Gottron papules (red patchy squamous papules on the back of knuckles); ③ The level of one muscle enzyme in serum was increased; ④ Positive myositis antibody; ⑤Electromyography shows denervation and myopathy; ⑥ Muscle biopsies showed necrosis and inflammation.
- The classification criteria of RJDM must meet ① and any of the criteria②-④: ① Patients who are intolerant or unresponsive to glucocorticoids and at least 2 immunosuppressants, adequate hormone therapy and duration of at least 6 months; ② The disease progresses rapidly and/or involves organs such as lungs, heart and gastrointestinal tract; ③ Calcification of subcutaneous or muscle and joint tissues; ④ Repeated rashes or skin ulcers.
- myositis specific antibody positive, defined as MDA-5, NXP2, TIF-1γ, Ro-52 and any other positive;
- If the patient has SRP or HMGCR antibody positive immune-mediated necrotizing myopathy equivalent to RJDM, the inclusion criteria of (2) - (4) can be met.
The functions of important organs are basically normal:
① Cardiac function: left ventricular ejection fraction (LVEF) ≥55%, no obvious abnormality in electrocardiogram;
② Renal function: eGFR≥30ML/min/1.73m2;
③ Liver function: AST and ALT≤3.0 ULN, total bilirubin ≤2.0×ULN;
④ Lung function: Lung function is basically normal, SpO2≥92%;
- Have the criteria for simple or intravenous blood collection, and no other contraindications for cell collection;
- The subject of childbearing age has a negative urine pregnancy test result and agrees to take effective contraceptive measures during the test period until 1 year after the infusion;
- The patient or his/her guardian agrees to participate in this clinical trial and signs an informed consent indicating that he/she understands the purpose and procedure of this clinical trial and is willing to participate in the study.
Exclusion Criteria:
- Had previously received CAR T cell therapy;
- Have other autoimmune or rheumatic diseases other than JDM;
- primary immunodeficiency or severe secondary immunodeficiency that has not been corrected;
- accompanied by serious infectious diseases, including but not limited to active tuberculosis, latent tuberculosis infection, active viral hepatitis, etc.;
- Evidence of active malignant disease or diagnosis of malignant tumor (including hematological malignancies and solid tumors, except resected and cured skin basal cell carcinoma)
- Congenital heart disease or history of acute myocardial infarction within 6 months before screening, or severe arrhythmias (including multi-source frequent supraventricular tachycardia, ventricular tachycardia, etc.); Or combined with a large number of pericardial effusion, serious myocarditis, etc.; Or patients with unstable vital signs who need hypertensive drugs to maintain their blood pressure;
- suffering from other diseases that require long-term use of glucocorticoids or immunosuppressants;
- There is an active or uncontrollable infection that requires systemic treatment within 1 week prior to screening;
- Received solid organ transplantation or hematopoietic stem cell transplantation within 3 months before screening; Acute graft-versus-host disease (GVHD) of grade 2 or above was present within 2 weeks prior to screening;
- Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer greater than the normal reference value range; Or hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA titer greater than the normal reference value range; Or positive for human immunodeficiency virus (HIV) antibodies; Or syphilis test positive; Or cytomegalovirus (CMV) DNA test positive;
- Had received live vaccine within 4 weeks prior to screening;
- Positive blood pregnancy test;
- Patients with known malignant diseases such as tumors before screening;
- Patients who had participated in other clinical trials within 3 months prior to enrollment;
- Situations in which other investigators consider it inappropriate to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CD19-targeted CAR-T
The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).
|
Subjects underwent lymphocyte clearance chemotherapy and then received a single intravenous cell infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To evaluate the safety of CAR-T in the treatment of refractory juvenile dermatomyositis [Safety and Tolerability]
Time Frame: 28 days
|
The incidence of adverse events after CAR-T cell infusion was assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 5.0).including the type, frequency and severity of adverse events
|
28 days
|
|
To evaluate the efficacy of CAR-T in the treatment of refractory juvenile dermatomyositis [Effectiveness]
Time Frame: 2month,3months
|
Disease improvement rate: The number of subjects who achieved disease improvement as a percentage of all subjects who received transfusions.
|
2month,3months
|
|
Duration of Response (DOR) of CAR-T treatment in the treatment of refractory juvenile dermatomyositis [Effectiveness]
Time Frame: 2 years
|
DOR will be assessed from the first assessment of remission to the first assessment of recurrence or progression of the disease or death from any cause
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUCS of CD19 CAR-T cells [Cell dynamics]
Time Frame: 3 months
|
AUCS is defined as the area under the curve in 90 days
|
3 months
|
|
TMAX of CD19 CAR-T cells[Cell dynamics]
Time Frame: 3 months
|
TMAX is defined as the time to reach the highest concentration
|
3 months
|
|
CMAX of CD19 CAR-T cells [Cell dynamics]
Time Frame: 3 months
|
CMAX is defined as the highest concentration of CEA CAR-T cells expanded in peripheral blood
|
3 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To evaluate the effects of CD19-targeting CAR T cell preparations on the weight of children
Time Frame: 2 years
|
Weight in kilograms were monitored after transfusion until subjects reached 18 years of age
|
2 years
|
|
To evaluate the effects of CD19-targeting CAR T cell preparations on the height of children
Time Frame: 2 years
|
Height in meters were monitored after transfusion until subjects reached 18 years of age
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Meiping Lu, M.D, Children's Hospital ZheJiang University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PBC068
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.